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ABSTRACT 
 
Sarcoidosis is a systemic granulomatous disorder of unidentified etiology, with a 
heterogeneous clinical presentation. It is characterized by a reduced delayed-type 
hypersensitivity to tuberculin and common antigens. The balance between Th1, Th17 and 
Regulatory T(Treg) cells controls T-cell proliferation and activation.The Th17/Treg ratio in 
the peripheral blood and bronchoalveolar lavage fluidis increased in patients with active 
sarcoidosis. Amplified IL-17A expression in granulomas and the presence of IL-17A+, IL-
17A+IL-4+ and IL-17A+IFN-γ+ memory T helper cells in the circulation and BAL indicate 
Th17 cell involvement in granuloma induction and/or maintenance in sarcoidosis. 
Sarcoidosis should therefore be considered as a Th1/Th17 multisystem disorder and anti-IL-
17/Th17 approaches that control and reduce IL-17Amay be an option, therefore, for the 
treatment of sarcoidosis.Here we provide a short overview as to the role of Th17 cells as 
critical cells in the pathogenesis of sarcoidosis. 
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INTRODUCTION 
 
Sarcoidosis is a systemic granulomatous disorder of 
unidentified etiology, with a heterogeneous clinical 
presentation. 
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The majority of patients have lung and intrathoracic 
lymph node involvement. In most cases sarcoidosis is 
sub-acute and self-limiting; however, highmorbidity 
and mortalitymay result from pulmonary fibrosis or 
cardiac or neurological involvement.
1 
Although disease 
remission occurs in up to two-thirds of patients, others 
have chronic constant sarcoidosis which may lead to 
lung fibrosis.
2
 The lungs are involved in >90% of 
patients
3
 and histopathologically, sarcoidosis is the 
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existence of noncaseatingepithelioid granulomas with 
mononuclear cell infiltration and microarchitecture 
damage.
3
 Sarcoidosis is usually defined according to 
clinical and radiological definitions
1
although the 
detection of CD4 and CD8 T cells by flow cytometry is 
being increasingly used as a diagnostic tool.
4 
The 
heterogeneity of the disease ranges from no symptoms 
to severe respiratory insufficiency, cardiac death, 
neurological disease, and blindness.
5
Chest radiographis 
reported as abnormalin 95% of sarcoidpatients
6
with the 
most characteristic featurebeing bilateral hilar 
lymphadenopathy (BHL) which is seen in 50-80% of 
patients.
7
 
Granulomas are generated whenever macrophages 
are not able to degrade and completely eradicatean 
antigen. More specifically, in sarcoidosis 
multinucleated giant cells and epitheloid cells are 
present. Activated mononuclear cells and T cells 
accumulate around a granuloma and surrounding tissue 
indicating that ongoing immune stimulation is 
occurring.
8 
These immunoinflammatory processes are 
compartmentalized since enhanced immune cell 
activation is seen in organs with inactive or only 
modestly activated cells in the peripheral blood.
9 
As 
such, sarcoidosis can bedescribed as an “immune 
paradox” with the presence of peripheral anergy,as 
demonstrated by a reduced delayed-type 
hypersensitivity to tuberculin and common 
antigens
10
,despiteenhanced inflammation at disease 
sites.
11
 
A disequilibrium between effector and regulatory 
lymphocytes (Treg cells), notably CD4
+ 
CD25
bright
FoxP3
+
 cells may underpin this 
paradox.
11
Treg cells accumulate intheperipheryof the 
granuloma andperipheral bloodof patients with active 
sarcoidosis and exert anti-proliferative effects on and 
weakly suppress TNF-α production from naive T 
cells.
12 
Treg inactivation may lead to enhanced Th1 
cytokine patterns and an increase in Th17cell activity 
resulting inamplified T cell proliferation and 
activation.
13 
This review summarizes the evidence for 
arole of T cell subsets notably Th17 cells in the 
pathogenesis of sarcoidosis. 
 
T Helper 1(Th1) Cells 
Clinically sarcoidosis is characterized by peripheral 
blood T cell lymphopenia, accompanied by cutaneous 
anergy to tuberculin and other skin tests. However, 
there is a clear differentiation between local and 
systemic immune activation. There are 
increasednumbers of CD3
+
CD4
+ 
T cells observed in 
bronchoalveolar lavage (BAL) resulting in an increased 
CD4/CD8 ratio. Increased levels of Th1 cytokines are 
found in the BAL fluid (BALF) and sites of 
inflammation in sarcoidosis patients.
14, 15
 This is 
reflected in the presence of Th1CD4
+ 
T cells 
characterized by high TCR expression and by IFN-γ 
and Tbx21 gene expression in sarcoid tissue. Lung T 
cells in sarcoid patients are highly activated, expressing 
the IL-2 receptor (CD25), CD69 and CD26
16,17 
Thus, 
sarcoidosis bears the hallmarks of a Th1-mediated 
disease in which activated T cells and cytokines are 
associated with diseasepathogenesis.
18
 
 
Regulatory T Cells 
In addition to Th1 and Th2 subsets, recent reports 
have identified CD4
+
CD25
high
Foxp3
+ 
regulatory T cells 
(Tregs) and Th17 cells as the two new distinct subsets 
of CD4
+
T cells.
19,20 
Tregs are observed in and around 
kidney and lymph node granulomas in sarcoidosis 
patients where they proliferate as evidenced by 
elevated Ki-67 expression.
21 
However, their presence in 
blood and BAL of sarcoidosis patients 
presentsconflicting results. Idahli et al.
21 
found a 
decreased expression of Foxp3 mRNA in CD4
+
 BAL T 
cells and a reduced number of Foxp3
+
CD4
+
 T cells 
inthe BAL and blood of patients with sarcoidosis. In 
contrast, Miyara et al.
22 
found an increased number 
ofCD4
+
CD25
bright
Tregs in blood and BAL.In addition, 
an increase in activated/memory Tregs and a decrease 
inresting/naive Tregs in the blood of sarcoidosis 
patients has been reported.
23 
However, functional tests 
usingTregs from sarcoidosis patients have shown a 
decreased ability to suppress IFN-γ and TNF-α 
production by effector T cells.
24
 
 
T Helper17 (Th17) Cells  
There is a lack of data concerning human Th17 cell 
function compared to the vast array of knowledge 
associated with human Th1 and Th2 cell function in 
human immunopathology.
25-27
 Since recent studies 
have shown an altered Treg and Th17 cell ratio in many 
immune-mediated diseases including autoimmune 
arthritis, psoriasis, inflammatory bowel disease, 
systemic lupus erythematous,
28-30
 it was no surprise that 
there is an increased Th17/Treg ratio in the peripheral 
blood and BALFof patients with active 
sarcoidosis.
31
Importantly, a good response to 
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corticosteroid treatmentin sarcoidosis patients is 
associated with a shift in this ratio towards baseline. 
These results indicate that an immune imbalance 
between Th17 and Treg cells may play a key role in the 
pathogenesis of sarcoidosis and suggest that strategies 
designed to favoureither Treg cell expansion or the 
suppression of Th17 cell differentiation may be 
helpfulapproaches for the treatment of sarcoidosis.
31
 
The recruitment of IL-17-producing Th17 cells to 
granulomas is due to the release of cytokines and 
chemokines such as IL-1β, IL-6, IL-23, IL-12, IL-18, 
and CCL20 by locally and systemically activated 
macrophages
32-34
(Figure1). Recent studies have found 
an increase inIL-17A
+
CD4
+
 memory T cells in the 
peripheral blood and BAL of pulmonary sarcoidosis 
patients,
35 
implicating Th17 cells in the pathogenesis of 
sarcoidosis.
34, 36
 
IL-17 is emerging as an essential player in the host 
defence in several mammalian organs including the 
human lung
 37, 38
 particularly during the chronic 
inflammation seen with mycobacterial infection, 
autoimmune disorders and also with granuloma 
formation.
39,40 
IL-17 is required not only to clear the 
primary infection but also to establish effective 
memory cell responses and may be produced by CD4+ 
T cells and by T cells which produce IL-17 rapidly 
after infection.
41 
Increased levels of IL-17 have been 
reported in sarcoidgranulomas
42
 where it is thought to 
play a role in the formation and maturation of 
granulomas.
39, 43 
In addition, to its presence in 
granulomas, increased levels of IL-17A and of IL-17-
producing cells are seen in peripheral blood of patients 
with sarcoidosis.
42, 44 
As a consequence it has been 
proposed that IL-17-producing cells may be useful 
biomarkers for the prognosis of sarcoidosis.
44
It is 
hoped, therefore, that targeting IL-17 may have a 
similar therapeutic efficacy in some sarcoidosis patients 
as that seenin patients with rheumatoid arthritis 
orpsoriasis.
45
 
IL‑6 is known to promote the differentiation of T 
cells to Th17cells
46,47
 and there is a significant 
upregulation of IL-6, IL-17 as well as of IFN-γ in 
BALFof sarcoidosis patients.
51 
This is associated with 
the presence of IL-17A
+
, IL-17A
+
IL-4
+
 and IL-
17A
+
IFN-γ+ memory Th cells in the circulation and 
BAL of these patients.
48 
Peripheral blood Th17 cells 
have decreased expression of IFN-γ upon 
TCRstimulation
49 
which mediatesthe recruitment of 
CXCR3
+
 T cells into the lung following the production 
of the chemokinesCXCL9, CXCL10, and 
CXCL11.IFN-γ is a key mediator in the acquired 
immune response and is closely associated with Th1 
cells. The reduced expression of IFN fromTh1 and 
Th17 cells from sarcoidosis patients suggests that the 
resulting levels of IFN-γmay not be sufficient for the 
clearance of the antigenic agents driving sarcoidosis.
49 
Overall, based on the presence of IL-17
+
CD4 T cells in 
sarcoid lung tissue and the clear links with pathogenic 
mechanisms it may be better to describe sarcoidosis as 
a Th1/Th17multi-system disorder with the implication 
that targeting these cells that may treat thedisease.
13
 
 
 
 
 
Figure1. Schematic summary of cell interactions in sarcoid tissue. The granulomatous infiltrate is a highly inflammatory 
microenvironment, which promotes the differentiation of Th0 to Th1 and Th17. IL-12 is 
instrumentalinbiasingTcellstowardtheTh1 lineage; IL-6,TGF-β, andIL-23providesignalsforTh17differentiation. 
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Other IL-17-Associated Cytokines  
IL-23 is a key cytokine for the induction ofTh17
56 
and its gene expression is increased in cutaneous 
sarcoidosis.
50 
IL-23 mRNA expression is also up-
regulated in two thirds of pulmonary sarcoidosis 
patients despite no significant expression ofIL-17 
mRNA.
51 
IL-23 and TGF-β play a role in the 
proliferation and differentiation of Th17 cells, which 
produce IL-17A, IL-17F, IL-21, and IL-22. Whilst IL-
17 is animportant member of the Th17 pathway, there 
are data suggesting that IL-21and IL-23 can act 
independently of IL-17 mRNA induction. This may 
explain the absence of IL-17 mRNA expression despite 
the presence of other Th17 pathway molecules.
52,53 
STAT3 has also been linked to the generation of Th17 
cells and the expression of IL-21 and its overexpression 
in peripheral blood in sarcoidosis indicates activation 
of the Th17pathway.
54 
The enhanced expression of the 
Th17 pathway genes including IL-23 and IL-21, but not 
of IL-17 mRNA, differentiates sarcoidosis from several 
other immune-mediated disorders such as psoriasis and 
Crohn’sdisease.55 Judson et al.56 confirm the 
upregulation of IL-12, IL-2, IL-23 and IFN in 
sarcoidosis. A clinical trial has been recently initiated 
to test an anti-IL-12p40 monoclonal antibody in 
sarcoidosis.
57 
 
SUMMARY AND CONCLUSION 
 
There are several lines of evidence implicating an 
involvement of pro-inflammatory Th17-lineage 
cytokines in sarcoidosis: (1) elevated numbers of 
circulating IL-17A
+
 memory Th cells, (2) increased 
presence of IL-17A
+
 cells, particularly IL-17A
+
IFN-γ+ 
and IL-17A
+
IL-4
+
 cells in BAL samples of sarcoidosis 
patients, (3) enhanced numbers of IL-17A-producing T 
cells in the lamina propria of sarcoidlung, (4) increased 
numbers of IL-22
+
 cells, especially in subepithelial 
regions, in granuloma-containing biopsies, (5) 
differential distribution of IL-17A
+
 and IL-22
+
 T cells 
in local granulomas, BAL and the circulation of 
sarcoidosis patients and (6) no evidence of increased 
IL-17A production by other Tγδ or CD8+ T cells.34 As 
such sarcoidosis may be considered as a Th1/Th17 
disorderthat affects many organs.
13 
Th1 and Th17 cells 
are the main T cell subtypes involved in the 
immunopathogenesis of sarcoidosis and it is becoming 
evident that IL-17Aplays a significant role in disease 
progression. This suggests that the control and 
reduction of IL-17Aor the suppression of Th17 cells 
should be investigated as an option for the treatment of 
sarcoidosis.Clinical trials of the fully humanized anti-
IL-17A antibody, AIN457, reduced theinflammation 
and decreasedthe disease activity in RA, psoriasis and 
non-infectious uveitishighlighting the efficacy and 
safety of this approach.
58 
In conclusion, modulation of 
Th17 cells and cytokines may be an attractive 
alternative method for the future treatment of 
sarcoidosis. 
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